Drug Trial Radar · NCT05966493
A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED
Last checked: Nov 19, 2026Latest source record: Jul 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
84
Planned (sponsor's estimate)
Start
Aug 17, 2023
Primary completion
Dec 2025
Study completion Dec 2025
Sponsor
- Lead sponsor
- Glaukos CorporationIndustry
- Sponsor type
- Industry
- First posted
- Jul 28, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to evaluate the safety and efficacy of NEXAGON® (lufepirsen ophthalmic gel) (NEXAGON) in subjects with persistent corneal epithelial defects (PCED). The objectives of the study are to evaluate the safety and efficacy of NEXAGON in this population.
Conditions
- Persistent Corneal Epithelial Defect
Interventions
lufepirsen high doseDrug
Lufepirsen is an unmodified connexin43 antisense oligonucleotide.
VehicleDrug
Matching vehicle without lufepirsen.
lufepirsen low doseDrug
Lufepirsen is an unmodified connexin43 antisense oligonucleotide.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Achieve Corneal Re-epithelialization Including Durability (CRC)Time frame: End of Study: 28 Days after achieving re-epithelialization
Locations
28 sites in 4 countries. Site status is shown where the registry gives one.
Glaukos Investigative Site
Dothan, Alabama · Recruiting
Glaukos Investigative Site
Petaluma, California · Recruiting
Glaukos Investigative Site
Torrance, California · Recruiting
Glaukos Investigative Site
Colorado Springs, Colorado · Recruiting
Glaukos Investigative Site
Grand Junction, Colorado · Recruiting
Glaukos Investigative Site
Bradenton, Florida · Recruiting
Glaukos Investigative Site
Fort Myers, Florida · Recruiting
Glaukos Investigative Site
South Miami, Florida · Recruiting
Glaukos Investigative Site
Atlanta, Georgia · Recruiting
Glaukos Investigative Site
Carmel, Indiana · Recruiting
Glaukos Investigative Site
Fraser, Michigan · Recruiting
Glaukos Investigative Site
Kansas City, Missouri · Recruiting
Glaukos Investigative Site
Kansas City, Missouri · Recruiting
Glaukos Investigative Site
Palisades Park, New Jersey · Recruiting
Glaukos Investigative Site
Shelby, North Carolina · Recruiting
Glaukos Investigative Site
Bala-Cynwyd, Pennsylvania · Recruiting
Glaukos Investigative Site
Nashville, Tennessee · Recruiting
Glaukos Investigative Site
Houston, Texas · Recruiting
Glaukos Investigative Site
San Antonio, Texas · Recruiting
Glaukos Investigative Site
Madison, Wisconsin · Recruiting
Glaukos Investigative Site
Milwaukee, Wisconsin · Recruiting
Glaukos Investigative Site
Mainz, Germany · Recruiting
Glaukos Investigative Site
München, Germany · Recruiting
Glaukos investigative Site
Messina, Italy · Recruiting
Glaukos Investigative Site
Barcelona, Spain · Recruiting
Glaukos Investigative Site
Madrid, Spain · Recruiting
Glaukos Investigative Site
Seville, Spain · Recruiting
Glaukos Investigative Site
Zaragoza, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.